Related Experiment Video
Updated: Sep 23, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Treatment of hypertensive patients with coexisting coronary arterial disease
Andrew Docherty1, Francis G Dunn
1The Cardiac Department, Stobhill Hospital, Glasgow, Scotland, UK.
Insights
Achieving target blood pressure is crucial for patients with hypertension and coronary artery disease. Combination therapy, often including beta-blockers and ACE inhibitors, is frequently necessary for effective blood pressure reduction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension and coronary artery disease (CAD) often present together and are frequently undertreated despite established guidelines.
- Recent studies (HOPE, LIFE, ALLHAT) reinforce the critical role of blood pressure reduction in managing CAD.
- Understanding medication mechanisms is secondary to achieving the primary goal of lowering blood pressure.
Purpose of the Study:
- To emphasize the importance of blood pressure control in patients with co-existing hypertension and coronary artery disease.
- To outline optimal therapeutic strategies for achieving target blood pressure in this patient population.
Main Methods:
- Review of current clinical guidelines and recent trial data (HOPE, LIFE, ALLHAT).
- Analysis of the prognostic benefits of various antihypertensive medication classes in CAD patients.
Main Results:
- Blood pressure reduction is paramount, irrespective of the specific antihypertensive agent used.
- Combination therapy is typically required to reach a target blood pressure of <140/80 mmHg.
- Beta-blockers and ACE inhibitors offer significant prognostic benefits; calcium channel blockers aid angina control; thiazide diuretics are effective.
Conclusions:
- Effective management of hypertension in CAD patients necessitates aggressive blood pressure lowering.
- Combination therapy, prioritizing beta-blockers and ACE inhibitors, is essential for most patients.
- Individualized treatment choices, considering medication efficacy and tolerability, are key.
Abstract:
Despite clear guidelines and an array of available antihypertensive medications, patients with hypertension and coronary artery disease are often inadequately treated. New data from HOPE, LIFE, and ALLHAT underscores the importance of blood pressure reduction for patients with coronary artery disease. Despite our improved understanding of the mechanism by which the various classes of antihypertensive medications achieve their effect, it remains the case that blood pressure reduction remains more important than the medication used to achieve the reduction. For most patients with coronary artery disease, combination therapy will be required to achieve a target blood pressure of less than 140/80. When tolerated, this therapy should include a beta-blocker and ACE inhibitor, both of which are of prognostic benefit for patients with coronary artery disease. There are also attractions in choosing calcium antagonists because of their efficacy in controlling anginal symptoms (Dihydropyridine calcium channel blockers if already on a beta-blocking agent and rate-limiting calcium channel blockers if beta blockers are contraindicated). Thiazide diuretics have proven themselves effective again in the ALLHAT study and are likely to be an integral part of treatment for the great majority of patients with coronary artery disease.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:23Hypertension V: Nursing Management
01:26Angina IV: Management